Fig. 2

Organoid-based drug screening. (A) Cell viability obtained by adding five drugs at 10 µM to 10 organoids for 96 h, compared with the control group. (B) Representative images of PDO, with cell viability ratios of 20%, 50%, and 100% relative to lytic agent treatment, scale bar: 500 μm. (Data are presented as mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001). PDO, patient-derived organoids.